Form 4: Pfizer Executive Mikael Dolsten Reports Stock Transaction
SEC Form 4 Filing
Mikael Dolsten, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon settlement of stock units.
Summary
- On February 28, 2024, Mikael Dolsten, President of R&D at Pfizer, reported a transaction involving Pfizer's common stock.
- The transaction involved the withholding of 21,437 shares to satisfy tax obligations related to the settlement of stock units from previously exercised stock appreciation rights.
- The price per share for the transaction was $27.04.
- Following the transaction, Dolsten directly owns 321,729 shares of Pfizer common stock and indirectly owns 1,981 shares through a Rule 16b-3 plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to insider transactions, and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax obligation fulfillment related to stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of stock transaction (withholding of shares for tax obligations). |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.